CY1124575T1 - Πολυμερικα συστηματα χορηγησης μακρας δρασης - Google Patents

Πολυμερικα συστηματα χορηγησης μακρας δρασης

Info

Publication number
CY1124575T1
CY1124575T1 CY20211100879T CY211100879T CY1124575T1 CY 1124575 T1 CY1124575 T1 CY 1124575T1 CY 20211100879 T CY20211100879 T CY 20211100879T CY 211100879 T CY211100879 T CY 211100879T CY 1124575 T1 CY1124575 T1 CY 1124575T1
Authority
CY
Cyprus
Prior art keywords
delivery
delivery systems
delivery system
compositions
carrier
Prior art date
Application number
CY20211100879T
Other languages
English (en)
Inventor
Thomas B. Ottoboni
Lee Ann Lynn Girotti
Original Assignee
Heron Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heron Therapeutics, Inc. filed Critical Heron Therapeutics, Inc.
Publication of CY1124575T1 publication Critical patent/CY1124575T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Συνθέσεις που αποτελούνται από έναν φορέα χορήγησης ή ένα σύστημα χορήγησης και έναν δραστικό παράγοντα διασπαρμένο εντός του φορέα ή του συστήματος χορήγησης, όπου ο φορέας ή το σύστημα χορήγησης περιέχει ένα πολυμερές πολυορθοεστέρα και έναν πολικό απρωτικό διαλύτη. Αποκαλύπτονται επίσης συστήματα χορήγησης χαμηλού ιξώδους για τη χορήγηση δραστικών παραγόντων. Τα συστήματα χορήγησης χαμηλού ιξώδους έχουν ένα πολυμερές πολυορθοεστέρα, έναν πολικό απρωτικό διαλύτη και έναν διαλύτη που περιέχει ένα τριγλυκερίδιο, παράγοντα μείωσης του ιξώδους. Οι συνθέσεις που περιγράφονται περιλαμβάνουν ένα τοπικό αναισθητικό τύπου αμιδίου ή ανιλιδίου της ταξινόμησης «καΐνη» και ένα μη στεροειδές αντιφλεγμονώδες φάρμακο (NSAID), μαζί με σχετικές μεθόδους, π.χ., για τη θεραπεία του μετεγχειρητικού πόνου ή για προφυλακτική θεραπεία πόνου. Οι συνθέσεις είναι κατάλληλες για χορήγηση μέσω, π.χ. απευθείας εφαρμογής και ενστάλαξης, ενδοδερμικής έγχυσης, υποδόριας έγχυσης και αποκλεισμού νεύρου (περινευρικά).
CY20211100879T 2014-04-21 2021-10-11 Πολυμερικα συστηματα χορηγησης μακρας δρασης CY1124575T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461982314P 2014-04-21 2014-04-21
US201461996788P 2014-05-14 2014-05-14
US201562131797P 2015-03-11 2015-03-11
PCT/US2015/026695 WO2015164272A2 (en) 2014-04-21 2015-04-20 Long-acting polymeric delivery systems

Publications (1)

Publication Number Publication Date
CY1124575T1 true CY1124575T1 (el) 2022-07-22

Family

ID=53002830

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100879T CY1124575T1 (el) 2014-04-21 2021-10-11 Πολυμερικα συστηματα χορηγησης μακρας δρασης

Country Status (21)

Country Link
US (4) US10213510B2 (el)
EP (2) EP3936115A1 (el)
JP (5) JP6702882B2 (el)
KR (2) KR102450730B1 (el)
CN (4) CN114886899B (el)
AU (3) AU2015249949B2 (el)
BR (1) BR112016024665B1 (el)
CA (2) CA2946281C (el)
CY (1) CY1124575T1 (el)
DK (1) DK3134068T3 (el)
ES (1) ES2893376T3 (el)
HR (1) HRP20211612T1 (el)
HU (1) HUE055973T2 (el)
LT (1) LT3134068T (el)
MX (2) MX2016013719A (el)
PL (1) PL3134068T3 (el)
PT (1) PT3134068T (el)
RS (1) RS62435B1 (el)
SI (1) SI3134068T1 (el)
TW (1) TWI675661B (el)
WO (1) WO2015164272A2 (el)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
CN105120839B (zh) 2013-02-28 2020-07-28 湖州惠中济世生物科技有限公司 可注射长效局麻药半固体制剂及其组成成分
US10220093B2 (en) 2013-02-28 2019-03-05 Mira Pharma Corporation Long-acting semi-solid lipid formulations
ES2837149T3 (es) 2014-04-21 2021-06-29 Heron Therapeutics Inc Composiciones de un poliortoéster y un excipiente de ácido orgánico
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems
CN114886899B (zh) 2014-04-21 2024-02-13 赫伦治疗有限公司 长效聚合物输送系统
WO2018048460A1 (en) * 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
US10449152B2 (en) * 2014-09-26 2019-10-22 Covidien Lp Drug loaded microspheres for post-operative chronic pain
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
FI20155779A (fi) 2015-10-30 2017-05-01 Solani Therapeutics Ltd Ei-steroidaalisen anti-inflammatorisen lääkkeen hidastetusti vapautuva annostelu
EP3458068A4 (en) * 2016-05-17 2020-01-22 Alberta Veterinary Laboratories Ltd TOPICAL COMPOSITION TO CONTROL PAIN IN ANIMALS
JP2020503324A (ja) * 2016-12-26 2020-01-30 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 慢性疼痛の処置のための組成物及び方法
JP2020536955A (ja) 2017-10-06 2020-12-17 ファウンドリー セラピューティクス， インコーポレイテッド 治療剤の制御放出のための埋込み可能なデポー
US10561606B2 (en) 2017-12-06 2020-02-18 Mira Pharma Corporation Injectable long-acting local anesthetic semi-solid gel formulations
US11426418B2 (en) 2017-12-06 2022-08-30 Mira Pharma Corporation Injectable long-acting semi-solid gel formulations
JP7046396B2 (ja) * 2017-12-06 2022-04-04 湖州惠中濟世生物科技有限公司 注射可能な長時間作用性局所麻酔薬半固形製剤
CN108158998B (zh) * 2017-12-28 2021-01-26 广州玻思韬控释药业有限公司 一种布比卡因多囊脂质体制备装置
KR20210060492A (ko) * 2018-09-07 2021-05-26 헤론 테라퓨틱스 인코포레이티드 수술 후 통증 치료
CN110935024B (zh) * 2018-09-21 2023-08-08 合肥合源药业有限公司 长效组合物
JP2022505572A (ja) * 2018-10-23 2022-01-14 ボーダックス バイオ インコーポレーテッド 術前および他の薬物との組み合わせでのメロキシカムの静脈内投与方法
CN109316602A (zh) * 2018-11-13 2019-02-12 西安力邦医药科技有限责任公司 一种长效镇痛并促进伤口愈合的复方缓释递药系统的组方与应用
CN113116823B (zh) * 2019-12-30 2024-02-20 江苏恒瑞医药股份有限公司 一种脂质体及其制备方法
CN115297854A (zh) 2020-01-10 2022-11-04 帕西拉制药股份有限公司 通过蛛网膜下腔给予缓释脂质体麻醉组合物治疗疼痛
CN115515581A (zh) 2020-01-10 2022-12-23 帕西拉制药股份有限公司 通过给予缓释脂质体麻醉组合物治疗疼痛
KR20220140711A (ko) * 2020-01-13 2022-10-18 듀렉트 코퍼레이션 불순물이 감소된 지속 방출 약물 전달 시스템 및 관련 방법
US20230080811A1 (en) 2020-01-14 2023-03-16 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Long-acting ropivacaine pharmaceutical composition, preparation method therefor and use thereof
CN114886840B (zh) * 2020-07-10 2023-08-25 南京海鲸药业股份有限公司 一种具有酸敏感降解、温敏性质的系列聚合物及其载药组合物
EP4274573A1 (en) 2021-01-11 2023-11-15 Pacira Pharmaceuticals, Inc. Treatment of hip pain with sustained-release liposomal anesthetic compositions
CN115068414B (zh) * 2021-03-16 2023-07-21 湖南慧泽生物医药科技有限公司 供注射用罗哌卡因长效溶液制剂及其制备方法
US11931459B2 (en) 2021-03-19 2024-03-19 Pacira Pharmaceuticals, Inc. Treatment of pain in pediatric patients by administration of sustained-release liposomal anesthetic compositions
WO2023105227A1 (en) * 2021-12-08 2023-06-15 Nanexa Ab New injectable combination formulation
KR20230115591A (ko) * 2022-01-27 2023-08-03 주식회사 티온랩테라퓨틱스 초기 방출 제어된 지질 융합 데포 조성물 및 이의 제조방법
WO2024052766A1 (en) * 2022-09-05 2024-03-14 Welfare Concepts Limited Cytotoxic agent for chemical disbudding and method
US11918565B1 (en) 2022-11-03 2024-03-05 Pacira Pharmaceuticals, Inc. Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4549010A (en) 1984-06-27 1985-10-22 Merck & Co., Inc. Bioerodible poly(ortho ester) thermoplastic elastomer from diketene diacetal
US4780319A (en) 1985-07-08 1988-10-25 Merck & Co., Inc. Organic acids as catalysts for the erosion of polymers
US4957998A (en) 1988-08-22 1990-09-18 Pharmaceutical Delivery Systems, Inc. Polymers containing acetal, carboxy-acetal, ortho ester and carboxyortho ester linkages
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
CA2176712C (en) 1993-11-16 2000-05-23 Mantripragada Sankaram Synthetic membrane vesicles with controlled release of encapsulated biologically active substances
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
DE69703430T2 (de) * 1996-01-05 2001-05-03 Advanced Polymer Systems Inc Polymere mit kontrolliertem physikalischen zustand und bioerodierbarkeit
IT1283252B1 (it) * 1996-03-15 1998-04-16 Pulitzer Italiana Soluzioni di piroxicam iniettabili per via parenterale
PT1014946E (pt) 1997-09-18 2010-07-06 Pacira Pharmaceuticals Inc COMPOSIÎES ANESTéSICAS LIPOSSOMAIS DE LIBERTAÆO SUSTENTADA
GB9808720D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
AU762794B2 (en) 1999-12-22 2003-07-03 Bgc Partners, Inc. Systems and methods for providing a trading interface
US6471688B1 (en) 2000-02-15 2002-10-29 Microsolutions, Inc. Osmotic pump drug delivery systems and methods
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US20050042194A1 (en) * 2000-05-11 2005-02-24 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6590059B2 (en) * 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
WO2003024357A2 (en) 2001-09-14 2003-03-27 Martin Francis J Microfabricated nanopore device for sustained release of therapeutic agent
DE10161077A1 (de) 2001-12-12 2003-06-18 Boehringer Ingelheim Vetmed Hochkonzentrierte stabile Meloxicamlösungen zur nadellosen Injektion
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
CN1822816A (zh) * 2003-05-30 2006-08-23 阿尔萨公司 可植入的弹性体储库组合物、其用途以及制备方法
US7666914B2 (en) 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
DK1781596T3 (da) * 2004-07-12 2009-01-19 Xenoport Inc Aminosyreafledte profarmaka af propofolsammensætninger og anvendelser deraf
JP5285275B2 (ja) 2004-09-17 2013-09-11 デュレクト コーポレーション 制御されたデリバリーシステム
RS53890B1 (en) * 2004-11-10 2015-08-31 Tolmar Therapeutics, Inc. STABILIZED POLYMER DELIVERY SYSTEM
US7655254B2 (en) 2005-02-03 2010-02-02 Intarcia Therapeutics, Inc. Implantable device for continuous delivery of interferon
US20070265329A1 (en) 2006-05-12 2007-11-15 Devang Shah T Methods for the prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
US20070264339A1 (en) 2006-05-12 2007-11-15 Ap Pharma, Inc. Base-stabilized polyorthoester formulations
US20070264338A1 (en) 2006-05-12 2007-11-15 Shah Devang T Base-stabilized polyorthoester formulations
WO2008005371A2 (en) * 2006-06-29 2008-01-10 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
WO2009062144A2 (en) 2007-11-09 2009-05-14 Berman David A Herpes treatment and dressing
US20100015049A1 (en) 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
WO2010019953A1 (en) 2008-08-15 2010-02-18 Arcion Therapeutics, Inc. High concentration local anesthetic formulations for treating non-neuropathic pain
US20100203102A1 (en) * 2009-02-10 2010-08-12 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using bupivacaine and an anti-onflammatory agent
US8603051B2 (en) 2009-02-17 2013-12-10 Kuvio, Inc. Implantable drug delivery devices
WO2010138918A1 (en) * 2009-05-29 2010-12-02 Pacira Pharmaceuticals, Inc. Hyaluronidase as an adjuvant for increasing the injection volume and dispersion of large diameter synthetic membrane vesicles containing a therapeutic agent
US8410140B2 (en) 2009-06-01 2013-04-02 The Regents Of The University Of Michigan Anesthetic methods and compositions
US20110033545A1 (en) 2009-08-06 2011-02-10 Absize, Inc. Topical pharmaceutical preparations having both a nanoparticle solution and a nanoparticle suspension and methods for the treatment of acute and chronic pain therewith
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
WO2012151442A1 (en) 2011-05-03 2012-11-08 Cummins Inc. Control techniques for an scr aftertreatment system
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
WO2014143635A1 (en) 2013-03-15 2014-09-18 Heron Therapeutics, Inc. Compositions of a polyorthoester and an aprotic solvent
CN114886899B (zh) 2014-04-21 2024-02-13 赫伦治疗有限公司 长效聚合物输送系统
WO2018048460A1 (en) 2014-04-21 2018-03-15 Heron Therapeutics, Inc. A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam
ES2837149T3 (es) 2014-04-21 2021-06-29 Heron Therapeutics Inc Composiciones de un poliortoéster y un excipiente de ácido orgánico
US9801945B2 (en) 2014-04-21 2017-10-31 Heron Therapeutics, Inc. Long-acting polymeric delivery systems

Also Published As

Publication number Publication date
AU2023202876A1 (en) 2023-05-25
JP2022017553A (ja) 2022-01-25
MX2021003558A (es) 2021-05-27
JP2019526601A (ja) 2019-09-19
KR20170005017A (ko) 2017-01-11
DK3134068T3 (da) 2021-10-04
AU2020207850B2 (en) 2023-02-23
US9694079B2 (en) 2017-07-04
CN114886899A (zh) 2022-08-12
EP3134068B1 (en) 2021-07-21
SI3134068T1 (sl) 2021-11-30
US20150297729A1 (en) 2015-10-22
PL3134068T3 (pl) 2021-12-20
CA2946281C (en) 2022-12-13
CN106535886A (zh) 2017-03-22
US20210220474A1 (en) 2021-07-22
US10213510B2 (en) 2019-02-26
TWI675661B (zh) 2019-11-01
AU2015249949A1 (en) 2016-11-03
CA2946281A1 (en) 2015-10-29
AU2020207850A1 (en) 2020-08-13
WO2015164272A2 (en) 2015-10-29
TW201605445A (zh) 2016-02-16
CA3174824A1 (en) 2015-10-29
JP2017513871A (ja) 2017-06-01
US10898575B2 (en) 2021-01-26
JP7181248B2 (ja) 2022-11-30
EP3936115A1 (en) 2022-01-12
AU2015249949B2 (en) 2020-07-30
HRP20211612T1 (hr) 2022-02-04
PT3134068T (pt) 2021-10-18
BR112016024665A2 (pt) 2018-06-19
CN115025099A (zh) 2022-09-09
JP2021138773A (ja) 2021-09-16
US20160375140A1 (en) 2016-12-29
WO2015164272A3 (en) 2015-12-17
CN114886899B (zh) 2024-02-13
MX2016013719A (es) 2017-07-11
JP6702882B2 (ja) 2020-06-03
RS62435B1 (sr) 2021-11-30
BR112016024665B1 (pt) 2023-04-11
LT3134068T (lt) 2021-10-11
HUE055973T2 (hu) 2022-01-28
JP2020114887A (ja) 2020-07-30
KR102450730B1 (ko) 2022-10-05
CN113908284A (zh) 2022-01-11
US11413350B2 (en) 2022-08-16
ES2893376T3 (es) 2022-02-08
EP3134068A2 (en) 2017-03-01
KR20220138419A (ko) 2022-10-12
US20170281778A1 (en) 2017-10-05
CN113908284B (zh) 2023-08-04

Similar Documents

Publication Publication Date Title
CY1124575T1 (el) Πολυμερικα συστηματα χορηγησης μακρας δρασης
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
AU2014318696B2 (en) Liquid protein formulations containing organophosphates
MX364396B (es) Poli(beta-amino esteres) modificados para suministro de farmaco.
SG10201902915VA (en) Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
NI201800038S (es) Dispositivo de administración de medicamento intranasal
EP3471796A4 (en) ASSEMBLIES AND METHODS FOR INFUSION PUMP SYSTEM DELIVERY ASSEMBLIES
MA40630A (fr) Dispositif d'administration d'un agent thérapeutique muni d'une canule et d'une aiguille pouvant avancer.
BR112015018904A2 (pt) limpador de desinfecção de orifício de acesso e conector sem agulha e cobertura de proteção antimicrobiana
CY1123720T1 (el) Συνθεσεις ενος πολυορθοεστερα και ενος εκδοχου οργανικου οξεος
EP4173615A3 (en) Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
WO2009014827A3 (en) Medical devices comprising polymeric drug delivery systems with drug solubility gradients
WO2016207119A8 (en) Devices and methods for drug administration and mixing, and training of proper techniques therefor
EP3421519A4 (en) BIODEGRADABLE AMPHIPHIL POLYMER SPECIFICALLY TREATED ON EGGSKIRTS, POLYMERIC VARIETY PRODUCED THEREFROM AND USE THEREOF
MY167777A (en) A pharmaceutical composition comprising electrohydrodynamically obtained fibres, the composition having improved residence time on the application site
WO2018141941A3 (en) Methods and systems for improving stability of pre-vapor formulations of e-vaping devices
MX2018001499A (es) Sistema para la entrega de polimeros liquidos para la administracion prolongada de farmacos.
MX2023004647A (es) Copolimeros de dibloque auto-montados compuestos de pegmema y segmentos polimericos que tienen farmaco.
WO2019055996A8 (en) Polymer nanodiscs for biotechnology and medical applications
MX2017004036A (es) Elementos de dispositivos medicos lubricos.
EP3556792A4 (en) PH-REACTIVE POLYMER AND ACTIVE SUBSTANCE RELEASE SYSTEM
GB2543241A (en) Synthetic crosslinked polymer additive for use in subterranean treatment fluids
MX2018004984A (es) Formulaciones de isotretinoina y usos y metodos de las mismas.
WO2016054404A3 (en) Medical fluid transfer and injection apparatus and method
BR112015028376A2 (pt) polímeros termoplásticos